Literature DB >> 7574471

Reversible dementia and apparent brain atrophy during valproate therapy.

O Papazian1, E Cañizales, I Alfonso, R Archila, M Duchowny, J Aicardi.   

Abstract

Two children developed severe cognitive and behavioral deterioration suggestive of a degenerative disease while being treated with sodium valproate for idiopathic, localization-related epilepsy with centrotemporal spikes. Magnetic resonance imaging revealed marked central and generalized cortical and cerebellar atrophy. In both patients, clinical symptoms and signs cleared in a few weeks following valproate withdrawal. The magnetic resonance imaging appearance improved within 3 months in 1 of the patients and normalized in both after 6 and 12 months. No metabolic changes were associated with the clinical or imaging abnormalities. Although the mechanism of this rare idiosyncratic complication of valproate therapy is unknown, we advocate discontinuing valproate therapy in all epileptic patients with neuromental deterioration or brain atrophy of unknown etiology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574471     DOI: 10.1002/ana.410380423

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Movement disorders in patients taking anticonvulsants.

Authors:  C Zadikoff; R P Munhoz; A N Asante; N Politzer; R Wennberg; P Carlen; A Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

2.  Fronto-striatal dysfunction in type 3 familial cortical myoclonic tremor epilepsy occurring during aging.

Authors:  Eloi Magnin; Marie Vidailhet; Ilham Ryff; Sabrina Ferreira; Pierre Labauge; Lucien Rumbach
Journal:  J Neurol       Date:  2012-06-27       Impact factor: 4.849

3.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease.

Authors:  A S Fleisher; D Truran; J T Mai; J B S Langbaum; P S Aisen; J L Cummings; C R Jack; M W Weiner; R G Thomas; L S Schneider; P N Tariot
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

4.  Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.

Authors:  T J Postma; C J van Groeningen; R J Witjes; J G Weerts; J H Kralendonk; J J Heimans
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

5.  Cerebellar atrophy in a child with valproate toxicity.

Authors:  Vidya B Ghosh; Seema Kapoor; Anjali Prakash; Sinchana Bhatt
Journal:  Indian J Pediatr       Date:  2011-01-19       Impact factor: 1.967

6.  Disease progression and brain atrophy in NMDAR encephalitis: Associated factor & clinical implication.

Authors:  Woo-Jin Lee; Soon-Tae Lee; Do-Yong Kim; Soyun Kim; Kon Chu
Journal:  Ann Clin Transl Neurol       Date:  2022-06-17       Impact factor: 5.430

7.  Association of Progressive Cerebellar Atrophy With Long-term Outcome in Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Authors:  Takahiro Iizuka; Juntaro Kaneko; Naomi Tominaga; Hidehiro Someko; Masaaki Nakamura; Daisuke Ishima; Eiji Kitamura; Ray Masuda; Eiichi Oguni; Toshiyuki Yanagisawa; Naomi Kanazawa; Josep Dalmau; Kazutoshi Nishiyama
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

8.  Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy.

Authors:  B C Bernhardt; K J Worsley; H Kim; A C Evans; A Bernasconi; N Bernasconi
Journal:  Neurology       Date:  2009-02-25       Impact factor: 9.910

Review 9.  "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.

Authors:  Yuxing Xia; Stefan Prokop; Benoit I Giasson
Journal:  Mol Neurodegener       Date:  2021-06-05       Impact factor: 14.195

10.  Clinical and Kinematic Features of Valproate-Induced Tremor and Differences with Essential Tremor.

Authors:  Giulia Paparella; Luca Angelini; Alessandro De Biase; Antonio Cannavacciuolo; Donato Colella; Carlo Di Bonaventura; Anna Teresa Giallonardo; Alfredo Berardelli; Matteo Bologna
Journal:  Cerebellum       Date:  2020-11-16       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.